Skip to main content

ESTUDIO PROSPECTIVO PARA IDENTIFICAR NUEVOS MARCADORES PLASMATICOS DE REPLICACION VIRAL EN PACIENTES CON HEPATITIS CRONICA POR VIRUS DE LA HEPATITIS B (VHB) Y/O DELTA (VHD)

PI17/02233

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre HOSPITAL VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up

  • Riveiro Barciela, Maria del Mar
  • Tabernero Caellas, David
  • Rodriguez-Algarra, Francisco
  • Palom Agusti, Adriana
  • Sopena Santisteve, Sara
  • Kuchta, Alison
  • Ferrer Costa, Roser
  • Quer Sivila, Josep
  • Pacín Ruíz, Beatriz
  • Vila Salvador, Marta
  • Casillas Gomez, Rosario
  • Garcia Garcia, Selene
  • Esteban Mur, Rafael
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Roade Tato, Maria luisa
  • Rando Segura, Ariadna
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Antiviral treatment; Biomonitoring, Tratamiento antiviral; Biomonitorización, Tractament antiviral; Biomonitorització, The measurement and interpretation of HBV DNA and RNA levels in HBV infected patients treated with antiviral therapy supports the objective of HBV disease management. Here, we quantified circulating HBV RNA through a standardized and sensitive assay in follow-up samples from both naive and treated patients as a marker of infection evolution. HBV DNA (HBV DNA for use in Cobas 6800/8800 Automated Roche Molecular Systems), RNA (Roche HBV RNA Investigational Assay for use in the Cobas 6800/8800; Roche), HBeAg and HBsAg (Elycsys HBsAg chemiluminescence immunoassay by Cobas 8000; Roche), and core-related antigen (Lumipulse G chemiluminescence assay; Fujirebio) levels were measured in cohorts of untreated or nucleos(t)ide treated, HBV-infected subjects in an outpatient hospital setting. HBV DNA levels in untreated people were 3.6 log10 higher than corresponding RNA levels and were stable over 5 years of observation. While only five of 52 treated patients had DNA levels below the lower limit of quantification (10 IU/mL) at the end of follow-up, 13 had HBV RNA levels persistently above this limit, including eight with undetectable DNA. In samples with undetectable core-related antigen we observed a median HBsAg titer 2.7-fold higher than in samples with undetectable RNA (adjusted P = 0.012). Detectable HBV RNA with undetectable HBV DNA was a negative predictor of HBsAg decrease to a level ≤100 IU/mL (P = 0.03). In naive patients the difference between HBV DNA and RNA was higher than previously reported. HBV RNA rapidly decreased during treatment. However, in some cases, it was detectable even after years of effective therapy, being a negative predictor of HBsAg decrease. The investigational RNA assay for use on the Cobas 6800/8800 instruments is a sensitive and standardized method that could be applied in general management of HBV infection. IMPORTANCE This study focused on the quantification of circulating HBV RNA by using a standardized and sensitive assay. Thanks to this system we observed a higher difference between circulating HBV DNA and RNA than previously reported. In treated patients, HBV RNA decreased together with DNA, although some patients presented detectable levels even after years of successful antiviral treatment, suggesting a persistent viral transcription. Of note, the detection of viral RNA when HBV DNA is undetectable was a negative predictor of HBsAg decrease to a level ≤100 IU/mL. This assay could be extremely helpful in HBV patients management to study viral transcription and to identify those treated patients that may achieve sustained viral suppression., This study was supported by grants from the Institute of Health Carlos III (grant PI17/02233 and PI18/01436) and by the European Regional Development Fund (ERDF). The funders had no role in study design, data collection, interpretation, or the decision to submit the work for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype

  • Roade Tato, Maria Luisa
  • Riveiro Barciela, Maria del Mar
  • Palom Agusti, Adriana
  • Rodríguez Frias, Francisco
  • Bes Maijo, Marta
  • Salcedo Allende, Maria Teresa
  • Casillas Gomez, Rosario
  • Vargas Accarino, Elena
  • Tabernero Caellas, David
  • Sauleda Oliveras, Silvia
  • Esteban Mur, Rafael
  • Rando Segura, Ariadna
  • Buti Ferret, Maria
HBV DNA; Hepatitis B virus; Inactive carrier, ADN del VHB; Virus de la hepatitis B; Portador inactivo, ADN del VHB; Virus de l'hepatitis B; Portador inactiu, Background and Aims Hepatitis B virus (HBV) biomarkers have been used for a better categorization of patients, even though the lack of simple algorithms and the impact of genotypes limit their application. Our aim was to assess the usefulness of noninvasive markers for the identification of HBV inactive carriers (ICs) in a single-point evaluation and to design a predictive model for their identification. Methods This retrospective-prospective study included 343 consecutive HBeAg-negative individuals. Clinical, analytical, and virological data were collected, and a liver biopsy was performed if needed. Subjects were classified at the end of follow-up as ICs, chronic hepatitis B and gray zone.A predictive model was constructed, and validated by 1000-bootstrap samples. Results After 39 months of follow-up, 298 subjects were ICs, 36 were chronic hepatitis B CHB, and nine were gray zone. Eighty-nine (25.9%) individuals required a liver biopsy. Baseline HBV DNA hazard ratio (HR) 6.0, p<0.001), HBV core-related antigen (HBcrAg) (HR 6.5, p<0.001), and elastography (HR 4.6, p<0.001) were independently associated with the IC stage. The ACE score (HBV DNA, HBcrAg, elastography), obtained by bootstrapping, yielded an area under the receiver operating characteristics (AUROC) of 0.925 (95% CI: 0.880–0.970, p<0.001) for identification of ICs. The AUROC for genotype D was 0.95, 0.96 for A, 0.90 for E, and 0.88 for H/F. An ACE score of <1 had a positive predictive value of 99.5%, and a score ≤12 points had a diagnostic accuracy of 93.8%. Conclusions Low baseline HBV DNA, HBcrAg, and liver stiffness were independently associated with the IC phase. A score including those variables identified ICs at a single-point evaluation, and might be applied to implement less intensive follow-up strategies., This study received partial financial support from Instituto de Salud Carlos III (PI17/02233 and PI20/01692).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers

  • Roade, Luisa
  • Pfefferkorn, Maria
  • Sopena, Sara
  • Bes Maijo, Marta
  • Casillas, Rosario
  • Tabernero, David
  • esteban, rafael
  • Riveiro-Barciela, Mar
  • Palom, Adriana
  • Rando Segura, Ariadna
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Buti Ferret, Maria
HBsAg proteins; Hepatitis D; Surface antigen, Proteínas HBsAg; Hepatitis D; Antígeno de superficie, Proteïnes HBsAg; Hepatitis D; Antigen de superfície, Background & Aims HBsAg proteins are useful to identify HBV inactive carriers (ICs), but data on chronic hepatitis D (CHD) are scarce. This study aimed to describe HBsAg composition in CHD, its changes during the evolution, and the potential association with clinical outcomes. In addition, we assess the composition of HBsAg across different HBV genotypes and validate previous results on HBsAg proteins in an independent HBV cohort. Methods Quantitative HBsAg, medium HBsAg proteins (MHBs), and large HBsAg proteins (LHBs) were measured in two cohorts. The first cohort consisted of patients with CHD. A cross-sectional study of samples from two European institutions (N = 46) was conducted. Outcomes were assessed in a retrospective–prospective study of those patients with a follow-up of >1 year (n = 36), and the longitudinal evolution of HBsAg proteins in those with samples >5 years apart (n = 12) was analysed. The second cohort consisted of patients with HBeAg-negative HBV, and a cross-sectional study was performed (N = 141). Results Forty-one (89%) patients with CHD had detectable HDV-RNA, and the presence of HDV-RNA was associated with higher LHBs proportion (p = 0.010). Baseline MHBs (p = 0.051) and MHBs proportion (p = 0.086) tended to be higher in those developing clinical outcomes (9/36, 25%) after a median follow-up of 5.9 years. Patients in which HDV-RNA became spontaneously undetectable during follow-up (5/31, 16.1%) tended to present lower MHBs proportion (p = 0.085). In the longitudinal study, changes in LHBs proportion were observed (p = 0.041), whereas MHBs proportion remained stable (p = 0.209). Regarding HBV, ICs showed lower LHBs proportion (p = 0.027). LHBs and MHBs differed significantly according to HBV genotype, regardless of the HBV phase. Conclusions Patients with CHD with detectable HDV-RNA presented higher LHBs proportion than those with undetectable HDV-RNA. A trend toward having higher baseline MHBs proportion was observed in patients who developed clinical outcomes or remained with detectable HDV-RNA. This study validates the different HBsAg composition in HBV ICs and reveals the HBV-genotype influence in HBsAg composition. Impact and implications The composition of HBsAg in chronic hepatitis D differs in patients with detectable and undetectable HDV viral load and may help predict the likelihood of achieving undetectable HDV viraemia and the development of clinical events such as decompensation. The composition of the surface antigen is also useful to distinguish inactive carriers of HBV, and it varies according to HBV genotype., This study received partial financial support from Instituto de Salud Carlos III (PI17/02233 and PI20/01692).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection

  • Godoy, Cristina|||0000-0001-5037-1916
  • Tabernero, David|||0000-0002-1146-4084
  • Sopena, Sara|||0000-0002-3309-5486
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • González, Carolina|||0000-0002-0169-5874
  • Casillas, Rosario|||0000-0002-6758-6734
  • Yll, Marçal|||0000-0002-7030-3360
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Lopez Martinez, Rosa|||0000-0002-8450-6986
  • Quer, Josep|||0000-0003-0014-084X
  • González-Aseguinolaza, Gloria|||0000-0002-1600-4562
  • Esteban, Rafael|||0000-0001-5280-392X
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
BACKGROUND Hepatitis delta virus (HDV) seems to strongly suppress hepatitis B virus (HBV) replication, although little is known about the mechanism of this interaction. Both these viruses show a dynamic distribution of mutants, resulting in viral quasispecies. Next-generation sequencing is a viable approach for analyzing the composition of these mutant spectra. As the regulatory hepatitis B X protein (HBx) is essential for HBV replication, determination of HBV X gene (HBX) quasispecies complexity in HBV/HDV infection compared to HBV mono-infection may provide information on the interactions between these two viruses. AIM To compare HBV quasispecies complexity in the HBX 5' region between chronic hepatitis delta (CHD) and chronic HBV mono-infected patients. METHODS Twenty-four untreated patients were included: 7/24 (29.2%) with HBeAg-negative chronic HBV infection (CI, previously termed inactive carriers), 8/24 (33.3%) with HBeAg-negative chronic hepatitis B (CHB) and 9/24 (37.5%) with CHD. A serum sample from each patient was first tested for HBV DNA levels. The HBX 5' region [nucleotides (nt) 1255-1611] was then PCR-amplified for subsequent next-generation sequencing (MiSeq, Illumina, United States). HBV quasispecies complexity in the region analyzed was evaluated using incidence-based indices (number of haplotypes and number of mutations), abundance-based indices (Hill numbers of order 1 and 2), and functional indices (mutation frequency and nucleotide diversity). We also evaluated the pattern of nucleotide changes to investigate which of them could be the cause of the quasispecies complexity. RESULTS CHB patients showed higher median HBV-DNA levels [5.4 logIU/mL, interquartile range (IQR) 3.5-7.9] than CHD (3.4 logIU/mL, IQR 3-7.6) (P = n.s.) or CI (3.2 logIU/mL, IQR 2.3-3.5) (P < 0.01) patients. The incidence and abundance indices indicated that HBV quasispecies complexity was significantly greater in CI than CHB. A similar trend was observed in CHD patients, although only Hill numbers of order 2 showed statistically significant differences (CHB 2.81, IQR 1.11-4.57 vs CHD 8.87, 6.56-11.18, P = 0.038). There were no significant differences in the functional indices, but CI and CHD patients also showed a trend towards greater complexity than CHB. No differences were found for any HBV quasispecies complexity indices between CHD and CI patients. G-to-A and C-to-T nucleotide changes, characteristic of APOBEC3G, were higher in CHD and CI than in CHB in genotype A haplotypes, but not in genotype D. The proportion of nt G-to-A vs A-to-G changes and C-to-T vs T-to-C changes in genotype A and D haplotypes in CHD patients showed no significant differences. In CHB and CI the results of these comparisons were dependent on HBV genotype. CONCLUSION The lower-replication CHD and CI groups show a trend to higher quasispecies complexity than the higher-replication CHB group. The mechanisms associated with this greater complexity require elucidation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype

  • Roade, Luisa|||0000-0002-8160-9613
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Palom, Adriana|||0000-0002-0130-1302
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Bes, Marta|||0000-0001-6103-072X
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Casillas, Rosario|||0000-0002-6758-6734
  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Tabernero, David|||0000-0002-1146-4084
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
Hepatitis B virus (HBV) biomarkers have been used for a better categorization of patients, even though the lack of simple algorithms and the impact of genotypes limit their application. Our aim was to assess the usefulness of noninvasive markers for the identification of HBV inactive carriers (ICs) in a single-point evaluation and to design a predictive model for their identification. This retrospective-prospective study included 343 consecutive HBeAg-negative individuals. Clinical, analytical, and virological data were collected, and a liver biopsy was performed if needed. Subjects were classified at the end of follow-up as ICs, chronic hepatitis B and gray zone.A predictive model was constructed, and validated by 1000-bootstrap samples. After 39 months of follow-up, 298 subjects were ICs, 36 were chronic hepatitis B CHB, and nine were gray zone. Eighty-nine (25.9%) individuals required a liver biopsy. Baseline HBV DNA hazard ratio (HR) 6.0, p <0.001), HBV core-related antigen (HBcrAg) (HR 6.5, p <0.001), and elastography (HR 4.6, p <0.001) were independently associated with the IC stage. The ACE score (HBV DNA, HBcrAg, elastography), obtained by bootstrapping, yielded an area under the receiver operating characteristics (AUROC) of 0.925 (95% CI: 0.880-0.970, p <0.001) for identification of ICs. The AUROC for genotype D was 0.95, 0.96 for A, 0.90 for E, and 0.88 for H/F. An ACE score of <1 had a positive predictive value of 99.5%, and a score ≤12 points had a diagnostic accuracy of 93.8%. Low baseline HBV DNA, HBcrAg, and liver stiffness were independently associated with the IC phase. A score including those variables identified ICs at a single-point evaluation, and might be applied to implement less intensive follow-up strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients, a Promising Marker of Infection Follow-Up

  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Tabernero, David|||0000-0002-1146-4084
  • Rodriguez-Algarra, Francisco|||0000-0002-4134-2141
  • Palom, Adriana|||0000-0002-0130-1302
  • Sopena, Sara|||0000-0002-3309-5486
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Roade, Luisa|||0000-0002-8160-9613
  • Kuchta, Alison
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Quer, Josep|||0000-0003-0014-084X
  • Pacín Ruiz, Beatriz|||0000-0001-8718-6589
  • Vila, Marta|||0000-0001-9303-5189
  • Casillas, Rosario|||0000-0002-6758-6734
  • García-García, Selene|||0000-0001-7697-2058
  • Esteban, Rafael|||0000-0001-5280-392X
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
The measurement and interpretation of HBV DNA and RNA levels in HBV infected patients treated with antiviral therapy supports the objective of HBV disease management. Here, we quantified circulating HBV RNA through a standardized and sensitive assay in follow-up samples from both naive and treated patients as a marker of infection evolution. HBV DNA (HBV DNA for use in Cobas 6800/8800 Automated Roche Molecular Systems), RNA (Roche HBV RNA Investigational Assay for use in the Cobas 6800/8800; Roche), HBeAg and HBsAg (Elycsys HBsAg chemiluminescence immunoassay by Cobas 8000; Roche), and core-related antigen (Lumipulse G chemiluminescence assay; Fujirebio) levels were measured in cohorts of untreated or nucleos(t)ide treated, HBV-infected subjects in an outpatient hospital setting. HBV DNA levels in untreated people were 3.6 log higher than corresponding RNA levels and were stable over 5 years of observation. While only five of 52 treated patients had DNA levels below the lower limit of quantification (10 IU/mL) at the end of follow-up, 13 had HBV RNA levels persistently above this limit, including eight with undetectable DNA. In samples with undetectable core-related antigen we observed a median HBsAg titer 2.7-fold higher than in samples with undetectable RNA (adjusted P = 0.012). Detectable HBV RNA with undetectable HBV DNA was a negative predictor of HBsAg decrease to a level ≤100 IU/mL (P = 0.03). In naive patients the difference between HBV DNA and RNA was higher than previously reported. HBV RNA rapidly decreased during treatment. However, in some cases, it was detectable even after years of effective therapy, being a negative predictor of HBsAg decrease. The investigational RNA assay for use on the Cobas 6800/8800 instruments is a sensitive and standardized method that could be applied in general management of HBV infection. IMPORTANCE This study focused on the quantification of circulating HBV RNA by using a standardized and sensitive assay. Thanks to this system we observed a higher difference between circulating HBV DNA and RNA than previously reported. In treated patients, HBV RNA decreased together with DNA, although some patients presented detectable levels even after years of successful antiviral treatment, suggesting a persistent viral transcription. Of note, the detection of viral RNA when HBV DNA is undetectable was a negative predictor of HBsAg decrease to a level ≤100 IU/mL. This assay could be extremely helpful in HBV patients management to study viral transcription and to identify those treated patients that may achieve sustained viral suppression.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers

  • Roade, Luisa
  • Pfefferkorn, Maria
  • Sopena, Sara
  • Bes Maijo, Marta
  • Casillas, Rosario
  • Tabernero, David
  • esteban, rafael
  • Riveiro-Barciela, Mar
  • Palom, Adriana
  • Rando Segura, Ariadna
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Buti Ferret, Maria
HBsAg proteins; Hepatitis D; Surface antigen, Proteínas HBsAg; Hepatitis D; Antígeno de superficie, Proteïnes HBsAg; Hepatitis D; Antigen de superfície, Background & Aims HBsAg proteins are useful to identify HBV inactive carriers (ICs), but data on chronic hepatitis D (CHD) are scarce. This study aimed to describe HBsAg composition in CHD, its changes during the evolution, and the potential association with clinical outcomes. In addition, we assess the composition of HBsAg across different HBV genotypes and validate previous results on HBsAg proteins in an independent HBV cohort. Methods Quantitative HBsAg, medium HBsAg proteins (MHBs), and large HBsAg proteins (LHBs) were measured in two cohorts. The first cohort consisted of patients with CHD. A cross-sectional study of samples from two European institutions (N = 46) was conducted. Outcomes were assessed in a retrospective–prospective study of those patients with a follow-up of >1 year (n = 36), and the longitudinal evolution of HBsAg proteins in those with samples >5 years apart (n = 12) was analysed. The second cohort consisted of patients with HBeAg-negative HBV, and a cross-sectional study was performed (N = 141). Results Forty-one (89%) patients with CHD had detectable HDV-RNA, and the presence of HDV-RNA was associated with higher LHBs proportion (p = 0.010). Baseline MHBs (p = 0.051) and MHBs proportion (p = 0.086) tended to be higher in those developing clinical outcomes (9/36, 25%) after a median follow-up of 5.9 years. Patients in which HDV-RNA became spontaneously undetectable during follow-up (5/31, 16.1%) tended to present lower MHBs proportion (p = 0.085). In the longitudinal study, changes in LHBs proportion were observed (p = 0.041), whereas MHBs proportion remained stable (p = 0.209). Regarding HBV, ICs showed lower LHBs proportion (p = 0.027). LHBs and MHBs differed significantly according to HBV genotype, regardless of the HBV phase. Conclusions Patients with CHD with detectable HDV-RNA presented higher LHBs proportion than those with undetectable HDV-RNA. A trend toward having higher baseline MHBs proportion was observed in patients who developed clinical outcomes or remained with detectable HDV-RNA. This study validates the different HBsAg composition in HBV ICs and reveals the HBV-genotype influence in HBsAg composition. Impact and implications The composition of HBsAg in chronic hepatitis D differs in patients with detectable and undetectable HDV viral load and may help predict the likelihood of achieving undetectable HDV viraemia and the development of clinical events such as decompensation. The composition of the surface antigen is also useful to distinguish inactive carriers of HBV, and it varies according to HBV genotype., This study received partial financial support from Instituto de Salud Carlos III (PI17/02233 and PI20/01692).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype

  • Roade Tato, Maria Luisa
  • Riveiro Barciela, Maria del Mar
  • Palom Agusti, Adriana
  • Rodríguez Frias, Francisco
  • Bes Maijo, Marta
  • Salcedo Allende, Maria Teresa
  • Casillas Gomez, Rosario
  • Vargas Accarino, Elena
  • Tabernero, David
  • Sauleda Oliveras, Silvia
  • Esteban Mur, Rafael
  • Rando Segura, Ariadna
  • Buti Ferret, Maria
HBV DNA; Hepatitis B virus; Inactive carrier, ADN del VHB; Virus de la hepatitis B; Portador inactivo, ADN del VHB; Virus de l'hepatitis B; Portador inactiu, Background and Aims Hepatitis B virus (HBV) biomarkers have been used for a better categorization of patients, even though the lack of simple algorithms and the impact of genotypes limit their application. Our aim was to assess the usefulness of noninvasive markers for the identification of HBV inactive carriers (ICs) in a single-point evaluation and to design a predictive model for their identification. Methods This retrospective-prospective study included 343 consecutive HBeAg-negative individuals. Clinical, analytical, and virological data were collected, and a liver biopsy was performed if needed. Subjects were classified at the end of follow-up as ICs, chronic hepatitis B and gray zone.A predictive model was constructed, and validated by 1000-bootstrap samples. Results After 39 months of follow-up, 298 subjects were ICs, 36 were chronic hepatitis B CHB, and nine were gray zone. Eighty-nine (25.9%) individuals required a liver biopsy. Baseline HBV DNA hazard ratio (HR) 6.0, p<0.001), HBV core-related antigen (HBcrAg) (HR 6.5, p<0.001), and elastography (HR 4.6, p<0.001) were independently associated with the IC stage. The ACE score (HBV DNA, HBcrAg, elastography), obtained by bootstrapping, yielded an area under the receiver operating characteristics (AUROC) of 0.925 (95% CI: 0.880–0.970, p<0.001) for identification of ICs. The AUROC for genotype D was 0.95, 0.96 for A, 0.90 for E, and 0.88 for H/F. An ACE score of <1 had a positive predictive value of 99.5%, and a score ≤12 points had a diagnostic accuracy of 93.8%. Conclusions Low baseline HBV DNA, HBcrAg, and liver stiffness were independently associated with the IC phase. A score including those variables identified ICs at a single-point evaluation, and might be applied to implement less intensive follow-up strategies., This study received partial financial support from Instituto de Salud Carlos III (PI17/02233 and PI20/01692).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up

  • Riveiro Barciela, Maria del Mar
  • Tabernero, David
  • Rodriguez-Algarra, Francisco
  • Palom Agusti, Adriana
  • Sopena Santisteve, Sara
  • Kuchta, Alison
  • Ferrer Costa, Roser
  • Quer Sivila, Josep
  • Pacín Ruíz, Beatriz
  • Vila Salvador, Marta
  • Casillas Gomez, Rosario
  • Garcia Garcia, Selene
  • Esteban Mur, Rafael
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Roade Tato, Maria luisa
  • Rando Segura, Ariadna
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Antiviral treatment; Biomonitoring, Tratamiento antiviral; Biomonitorización, Tractament antiviral; Biomonitorització, The measurement and interpretation of HBV DNA and RNA levels in HBV infected patients treated with antiviral therapy supports the objective of HBV disease management. Here, we quantified circulating HBV RNA through a standardized and sensitive assay in follow-up samples from both naive and treated patients as a marker of infection evolution. HBV DNA (HBV DNA for use in Cobas 6800/8800 Automated Roche Molecular Systems), RNA (Roche HBV RNA Investigational Assay for use in the Cobas 6800/8800; Roche), HBeAg and HBsAg (Elycsys HBsAg chemiluminescence immunoassay by Cobas 8000; Roche), and core-related antigen (Lumipulse G chemiluminescence assay; Fujirebio) levels were measured in cohorts of untreated or nucleos(t)ide treated, HBV-infected subjects in an outpatient hospital setting. HBV DNA levels in untreated people were 3.6 log10 higher than corresponding RNA levels and were stable over 5 years of observation. While only five of 52 treated patients had DNA levels below the lower limit of quantification (10 IU/mL) at the end of follow-up, 13 had HBV RNA levels persistently above this limit, including eight with undetectable DNA. In samples with undetectable core-related antigen we observed a median HBsAg titer 2.7-fold higher than in samples with undetectable RNA (adjusted P = 0.012). Detectable HBV RNA with undetectable HBV DNA was a negative predictor of HBsAg decrease to a level ≤100 IU/mL (P = 0.03). In naive patients the difference between HBV DNA and RNA was higher than previously reported. HBV RNA rapidly decreased during treatment. However, in some cases, it was detectable even after years of effective therapy, being a negative predictor of HBsAg decrease. The investigational RNA assay for use on the Cobas 6800/8800 instruments is a sensitive and standardized method that could be applied in general management of HBV infection. IMPORTANCE This study focused on the quantification of circulating HBV RNA by using a standardized and sensitive assay. Thanks to this system we observed a higher difference between circulating HBV DNA and RNA than previously reported. In treated patients, HBV RNA decreased together with DNA, although some patients presented detectable levels even after years of successful antiviral treatment, suggesting a persistent viral transcription. Of note, the detection of viral RNA when HBV DNA is undetectable was a negative predictor of HBsAg decrease to a level ≤100 IU/mL. This assay could be extremely helpful in HBV patients management to study viral transcription and to identify those treated patients that may achieve sustained viral suppression., This study was supported by grants from the Institute of Health Carlos III (grant PI17/02233 and PI18/01436) and by the European Regional Development Fund (ERDF). The funders had no role in study design, data collection, interpretation, or the decision to submit the work for publication.